Pandion Therapeutics Holdco LLC

Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA.

-  Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024

Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update

Pandion Therapeutics Inc. PAND, +37.77% started its public life with a bang, as biotechnology company's stock opened 50% above where the upsized initial public offering was priced.

Pandion Therapeutics stock shot up 50% at its open

Pandion Therapeutics Inc.  raised more than expected in its initial public offering, which was upsized to 7.5 million shares and priced at $18.

News for Pandion Therapeutics Holdco LLC Stock (PAND)